NO20084810L - Rekombinant svekkede clostridium-organismer og vaksine - Google Patents

Rekombinant svekkede clostridium-organismer og vaksine

Info

Publication number
NO20084810L
NO20084810L NO20084810A NO20084810A NO20084810L NO 20084810 L NO20084810 L NO 20084810L NO 20084810 A NO20084810 A NO 20084810A NO 20084810 A NO20084810 A NO 20084810A NO 20084810 L NO20084810 L NO 20084810L
Authority
NO
Norway
Prior art keywords
organisms
alpha toxin
vaccine
attenuated
recombinant attenuated
Prior art date
Application number
NO20084810A
Other languages
English (en)
Norwegian (no)
Inventor
Mark D Cochran
Gary Petersen
Steven V Lair
Richard Synenki
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of NO20084810L publication Critical patent/NO20084810L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fodder In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Feed For Specific Animals (AREA)
NO20084810A 2006-04-17 2008-11-14 Rekombinant svekkede clostridium-organismer og vaksine NO20084810L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79255306P 2006-04-17 2006-04-17
PCT/US2007/009135 WO2007123850A2 (en) 2006-04-17 2007-04-12 Recombinant attenuated clostridium organisms and vaccine

Publications (1)

Publication Number Publication Date
NO20084810L true NO20084810L (no) 2009-01-16

Family

ID=38625523

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084810A NO20084810L (no) 2006-04-17 2008-11-14 Rekombinant svekkede clostridium-organismer og vaksine

Country Status (23)

Country Link
US (3) US7732187B2 (pt)
EP (2) EP2368571A1 (pt)
JP (2) JP5551933B2 (pt)
KR (1) KR20080110908A (pt)
CN (1) CN101489584B (pt)
AR (2) AR060471A1 (pt)
AU (1) AU2007240949B2 (pt)
BR (1) BRPI0711572A2 (pt)
CA (1) CA2649426C (pt)
CO (1) CO6140037A2 (pt)
EC (1) ECSP088827A (pt)
ES (1) ES2401810T3 (pt)
IL (1) IL194714A (pt)
MX (1) MX2008013451A (pt)
NO (1) NO20084810L (pt)
NZ (1) NZ571970A (pt)
PE (1) PE20080167A1 (pt)
PL (1) PL2007420T3 (pt)
RU (2) RU2445364C2 (pt)
TW (1) TWI338045B (pt)
UA (2) UA109105C2 (pt)
WO (1) WO2007123850A2 (pt)
ZA (1) ZA200808872B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US20060083750A1 (en) * 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
JP2011519049A (ja) * 2008-04-29 2011-06-30 イミューンエクサイト インコーポレイテッド 免疫調節組成物およびその使用方法
EP2613802A4 (en) * 2010-09-10 2014-03-26 Viropharma Inc ENVIRONMENTAL CLOSTRIDAL BACTERIOTHERAPY AND ASSOCIATED FORMULATIONS AND METHODS OF MAKING AND USING SAME
GEP201706766B (en) 2011-07-22 2017-10-25 Los Angeles Biomedical Res Center Methods and compositions for vaccinating against staphylococcus aureus
AR090219A1 (es) * 2012-03-02 2014-10-29 Regeneron Pharma Anticuerpos humanos frente a toxinas de clostridium difficile
ES2759583T3 (es) 2012-10-26 2020-05-11 Intervet Int Bv Vacunas de Salmonella de protección cruzada
US10130691B2 (en) 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
EP3426287A4 (en) 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
CN109602898B (zh) * 2018-12-28 2022-02-22 江苏省农业科学院 一种产气荚膜梭菌α毒素基因工程疫苗及其制备方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
GB202019767D0 (en) 2020-12-15 2021-01-27 Chain Biotechnology Ltd Compostitions and methods
CN114621963A (zh) * 2022-03-11 2022-06-14 牧原食品股份有限公司 一种猪魏氏梭菌a型的亚单位疫苗及其制备
CN116970505A (zh) * 2022-04-22 2023-10-31 金宇保灵生物药品有限公司 一种A型产气荚膜梭菌α毒素的产毒培养基及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1483042A (en) * 1974-07-29 1977-08-17 Lapointe J Anti-tumour product of bacterial origin
SU627611A1 (ru) 1977-09-30 1980-02-05 В.П. Землякова Вакцинный препарат в.п. земл ковой против клостридиозов животных и птиц
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
NZ253189A (en) * 1992-05-20 1996-08-27 Secr Defence Peptides comprising amino acid sequences of clostridium perfringens alpha toxins, vaccines containing them, antibodies and their use
GB9605222D0 (en) 1996-03-12 1996-05-15 Secr Defence Clostridium perfringens epsilon toxin vaccines
ES2276448T3 (es) * 1997-06-20 2007-06-16 Intervet International Bv Vacuna contra clostridium perfringens.
RU2129441C1 (ru) * 1997-12-10 1999-04-27 Пирожков Михаил Константинович Вакцина, ассоциированная против анаэробной энтеротоксемии и эшерихиоза поросят
US6399074B1 (en) * 1998-07-24 2002-06-04 Megan Health, Inc. Live attenuated salmonella vaccines to control avian pathogens
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US6908620B2 (en) * 2002-12-09 2005-06-21 University Of Georgia Research Foundation, Inc. Coccidial vaccine and methods of making and using same
JP2007512006A (ja) * 2003-11-10 2007-05-17 ザ ユーエービー リサーチ ファウンデーション 細菌輸送およびｃｎｓ侵襲を低減させるための組成物およびこの組成物を使用する方法
MY149604A (en) 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine

Also Published As

Publication number Publication date
RU2593945C2 (ru) 2016-08-10
WO2007123850A2 (en) 2007-11-01
RU2445364C2 (ru) 2012-03-20
US7972604B2 (en) 2011-07-05
PE20080167A1 (es) 2008-03-10
RU2008144913A (ru) 2010-05-27
IL194714A0 (en) 2011-08-01
IL194714A (en) 2015-03-31
JP2013255518A (ja) 2013-12-26
CN101489584B (zh) 2013-05-01
ES2401810T3 (es) 2013-04-24
NZ571970A (en) 2012-02-24
AR060471A1 (es) 2008-06-18
MX2008013451A (es) 2008-10-30
AU2007240949A1 (en) 2007-11-01
US20110008389A1 (en) 2011-01-13
TWI338045B (en) 2011-03-01
EP2007420B1 (en) 2013-03-06
KR20080110908A (ko) 2008-12-19
EP2368571A1 (en) 2011-09-28
US20100166800A1 (en) 2010-07-01
RU2011147308A (ru) 2013-05-27
BRPI0711572A2 (pt) 2011-11-16
JP2009533071A (ja) 2009-09-17
AR079941A2 (es) 2012-02-29
ZA200808872B (en) 2009-11-25
CA2649426A1 (en) 2007-11-01
US20070286874A1 (en) 2007-12-13
CN101489584A (zh) 2009-07-22
UA95951C2 (en) 2011-09-26
JP5551933B2 (ja) 2014-07-16
PL2007420T3 (pl) 2013-08-30
UA109105C2 (uk) 2015-07-27
EP2007420A2 (en) 2008-12-31
AU2007240949B2 (en) 2013-03-14
HK1125315A1 (en) 2009-08-07
TW200801182A (en) 2008-01-01
WO2007123850A3 (en) 2008-03-06
CO6140037A2 (es) 2010-03-19
ECSP088827A (es) 2008-11-27
CA2649426C (en) 2014-04-01
US7732187B2 (en) 2010-06-08
US7807456B2 (en) 2010-10-05

Similar Documents

Publication Publication Date Title
NO20084810L (no) Rekombinant svekkede clostridium-organismer og vaksine
ES2566740T3 (es) Vacunas y agentes terapéuticos de GAS en combinación
NZ594457A (en) Compositions and methods for the delivery of oxygen
AU2019311658A8 (en) Novel hyaluronidase variants and pharmaceutical composition comprising the same
NO20076360L (no) Dengue serotype 2 attenuert stamme
MY139896A (en) Improved prrs vaccines
SA521430342B1 (ar) تركيبة سائلة تشتمل على جسم مضاد لمستقبل ألفا إنترليوكين -4 البشري
ZA202204373B (en) Development of a novel live attenuated african swine fever vaccine based in the deletion of gene i177l
NZ576188A (en) Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
NZ593893A (en) Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases
BR0309570A (pt) Fatores camp quiméricos para vacinação contra infecção por streptococcus
ATE521627T1 (de) Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteins
MY144689A (en) Dengue serotype 1 attenuated strain
ES2670799T3 (es) Inmunógenos desintoxicados de Escherichia coli
DE60011560D1 (de) Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
BR0309491A (pt) Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes
MX381494B (es) Trigo con nuevos alelos de rht-b1.
DE602004015418D1 (de) Rekombinantes mva und verfahren zur erzeugung davon
MXPA05008774A (es) Cepas atenuadas de vibrio cholerae mejoradas en su seguridad ambiental presentadas en forma liofilizada para la vacunacion por via oral.
DK1937712T3 (da) Polynukleotid fra Haemophilus parasuis samt dets anvendelse
MX2022002612A (es) Composiciones de il-22 orales, intrarrectales u otras relacionadas con el intestino y metodos de uso de las mismas.
US20230322870A1 (en) Actinobacillus pleuropneumoniae vaccines

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application